A study found a surprising link between depression, suicide, and epilepsy, with people with epilepsy being 4 times more likely to have attempted suicide before having a seizure. Depression was also found to increase the risk of developing epilepsy.
A double-blind, placebo-controlled trial found that chromium picolinate supplementation significantly reduced carbohydrate cravings and improved symptoms of atypical depression. The study suggests that chromium picolinate may be beneficial for patients with severe carbohydrate craving, a characteristic symptom of the disorder.
Interpersonal and Social Rhythm Therapy (IPSRT) has been found to be an effective treatment for bipolar disorder, helping patients manage daily routines and relationships to prevent mania and depression. The study suggests that IPSRT is particularly beneficial for individuals with more regular social routines and better physical health.
A new project in Australia is exploring the economic benefits of treating depression in employees. The WORC Project has surveyed 80,000 employees and found that treating depression can recoup $338 per employee per year, improving morale and reducing costs associated with absenteeism and work under-productivity.
A 15-year longitudinal study found that individuals diagnosed with minor depression were more likely to develop major depression, particularly among young adults (18-29 years old) and women. The study also revealed that cancer and other chronic illnesses did not increase the risk of developing major depression.
Researchers at Harvard Medical School have identified a novel function for the molecule Par-4 as a binding partner for dopamine receptor D2. This discovery suggests that Par-4 may play a crucial role in regulating depression-like behaviors, providing a potential new target for antidepressants.
Researchers tested Seroquel on 542 patients with bipolar depression, finding that 50% responded quickly to treatment and experienced reduced suicidal thoughts. The study's findings suggest a potential new standard of care for bipolar disorder.
A new survey suggests that Seroquel provides significant quality of life improvements for bipolar patients, with 79% believing a successful treatment would lead to increased functionality and improved lifestyle. The medication has been shown to effectively manage symptoms of depression and anxiety in rapid-cycling patients.
A study of over 13,500 mothers and their partners found that paternal postnatal depression was associated with adverse emotional and behavioral problems in children, especially boys. The effects persisted even after controlling for maternal postnatal depression.
Researchers found that insomnia prolongs bouts of sadness and hopelessness, making recovery less likely. Elderly patients with insomnia are nearly 11 times more likely to still be depressed at six months than those sleeping well.
Researchers have found that bipolar disorder is associated with difficulties modulating brain regions that detect error and promote accurate responses. Additionally, a two-pronged pharmacologic approach of both a mood stabilizer and an antipsychotic may be necessary to treat both the depressive and manic phases of bipolar disorder.
Research found a strong association between depression severity and poor glycemic control among Hispanics with diabetes, particularly those with moderate-severe depression. This underlines the importance of identifying and treating depression to improve diabetic outcomes in this high-risk population.
Researchers discovered that omega-3 fatty acids are not linked to depression as previously thought, but rather increased arachidonic acid levels in the brain may be responsible. Omega-6 fatty acid intake could also play a role in controlling depression.
EQUETRO demonstrates significant reduction in manic symptoms for patients previously taking valproate or lithium, with average YMRS scores decreasing by 10.8 and 11.6 points, respectively. The medication is an effective treatment option for acute manic and mixed episodes associated with Bipolar I Disorder.
A study examining Seroquel treatment for bipolar depression found significant improvements in quality of life measures, with the most common adverse events including dry mouth and sedation. The results are promising for managing depressive symptoms associated with bipolar disorder.
Loneliness is a strong risk factor for depression among retirement community residents, linked to factors like social network size and grieving. Retirement communities can help by encouraging outside friendships, sending reminders, and forming support groups for vulnerable individuals.
A new study finds that treating depression in older adults improves their ability to perform tasks critical to independent living and slows physical decline. The study used collaborative care management and found improved outcomes for patients with late-life depression.
Researchers found a significant association between depression and ventricular tachycardia, a precursor to sudden cardiac death, in hospitalized heart attack patients. The risk of ventricular tachycardia increased with increased levels of depression.
A study found that bipolar disorder is prevalent among patients in an urban primary care clinic, with 9.8% screening positive for the condition. Patients who screened positive reported worse health-related quality of life and social impairment compared to those who did not screen positive.
Research suggests that people with a history of depression are at a higher risk of developing epilepsy, while those with epilepsy may be more likely to experience depression. Studies have found common biological mechanisms underlying both conditions, including abnormal neurotransmitter secretion patterns.
A new study finds that DHEA therapy is effective in reducing depression symptoms and improving sexual functioning in individuals with midlife-onset depression. Six weeks of DHEA treatment resulted in a 50% reduction in depression scores, compared to placebo, suggesting its potential as a second-line treatment option.
Children of depressed mothers exhibit higher levels of conduct problems, suggesting maternal depression disrupts caregiving environments. Maternal depression combined with antisocial personality disorder poses the greatest risk for children's ASB.
A collaborative care program for adolescent depression in primary care clinics significantly reduces symptoms, improves quality of life, and increases access to effective treatments. The study suggests that clinicians can effectively treat youth depression with a team-based approach.
A quality improvement intervention for adolescents improved depressive symptoms, mental health-related quality of life, and satisfaction with mental health care. The program also increased access to evidence-based treatments like psychotherapy and counseling.
Researchers engineered mice to lose glucocorticoid receptors, showing an increase in depression-like behaviors and impaired regulation of stress response. This study suggests that genetic makeup may play a role in triggering depression by affecting the brain's ability to regulate adrenal hormones.
Researchers found that extended-release carbamazepine capsules improved symptoms in patients with bipolar disorder, including those experiencing mania and mixed episodes. The treatment was generally well-tolerated, with few adverse events reported.
A new study by Dr. Katherine Hartmann found that women experience significant improvements in self-reported pelvic pain and depression two years after hysterectomy. The study involved nearly 1,300 women who reported a reduction in symptoms, with the group experiencing both conditions showing the most improvement.
A study published in the British Journal of Psychiatry found that electroconvulsive therapy (ECT) improves mood, quality of life, and activities of daily living in patients with major depression. Sixty-six percent of patients showed significant improvement after ECT treatment.
A new study reveals that stress activates the mania-linked enzyme PKC, leading to impaired cognitive functions in the prefrontal cortex and reduced memory-related cell firing. Inhibiting PKC may offer a fast-acting treatment for mania, with potential benefits for patients seeking emergency room care.
Parkinson's disease is often associated with depression, a condition that can significantly impact patients' lives. Research suggests that depression is part of the illness and not just a reaction to the disease.
A study by Dr. Kurt Kroenke found that depression is a risk factor for pain symptoms, with muscle pain and headaches being two or three times more common in people with depression. Physical symptoms may not respond to antidepressant treatment as well as emotional symptoms, and can linger longer.
Researchers found that women experiencing depressive symptoms, binge drinking, or smoking during pregnancy may be at risk for depression and alcohol use during the first postpartum year. Early identification and treatment of these comorbid conditions can benefit both mothers and children.
Researchers identify molecular pathway in brain that explains why patients with inflammatory diseases develop depression. By understanding this mechanism, scientists hope to help patients avoid depression while benefiting from immune-boosting treatments.
A study of 200 adults found that physicians often misattribute physical symptoms to causes other than depression. Patients with physical symptoms were less likely to accept antidepressants and showed improved outcomes when presented with psychological symptoms.
A national health survey found that depression in young women is associated with an increased risk of developing the metabolic syndrome, a cluster of factors linked to heart disease. The study also suggests that depression can cause physiological changes that increase the risk of heart disease.
Women with PTSD experience more medical conditions and poorer physical health compared to those with depression or no history of mental health issues. The study found that PTSD affects 17% of women under 45, while depression rates are higher in older age groups.
A study of 1,248 people with depression found that those who didn't recover from symptoms after routine treatment were more likely to experience persistent depression and report side effects from medication. These individuals often felt they received inadequate care from their doctors, leading to continued use of healthcare services.
A randomized trial of 542 patients with bipolar depression found Seroquel (quetiapine fumarate) to be effective in reducing symptoms, with a response rate of 50% compared to placebo. The study suggests that Seroquel may be a viable treatment option for bipolar disorder, particularly for patients who exhibit anxiety and agitation.
A NIH study found that combination therapy of psychotherapy and pharmacotherapy improved treatment adherence and reduced depression in injection drug users. The study showed nearly 40% of participants fully adherent to treatment were in remission, compared to 12% without treatment.
A twin study found a possible connection between depression and heart disease, with decreased heart rate variability (HRV) being a key factor. The study suggests that treating clinical depression, including minor forms, may help reduce the risk of heart disease by normalizing HRV.
A study of 278 men aged 45+ without depression found that low testosterone levels were associated with a higher incidence of diagnosed depression. Men with hypogonadism were 4.2 times more likely to be diagnosed with depression than those with normal testosterone levels.
A clinical trial found that depression improved in most patients after three months of drug therapy, but 24% persisted with high scores. Moderate to severe pain at the start of treatment was associated with a higher risk of poor response.
A study of 91 patients with traumatic brain injury (TBI) found that depression was a common complication, affecting 33% during the first year. TBI patients with depression were also more likely to have mood and anxiety disorders, exhibiting aggressive behavior and reduced social functioning.
A new study has found that the starting dose of Lexapro is as effective as an optimally dosed Zoloft in treating depression. Patients treated with Lexapro experienced significant relief from depressive symptoms, with 75% achieving a 50% or better reduction in their Montgomery-Asberg Depression Rating Scale scores.
A recent study published in the American Journal of Public Health found that major depression was most prevalent among Hispanics, followed by African Americans and whites. The odds of depressive disorders were significantly higher among older Hispanics due to caregiving responsibilities.
A pioneering study using brain imaging has yielded new insights into treatment-resistant depression, revealing differences in brain activity between healthy individuals and those suffering from the condition. The research also highlights the potential for developing a new generation of antidepressants with unprecedented efficacy.
A double-blind study found that Risperdal significantly reduced 'manic' symptoms in patients with bipolar disorder, with treatment response achieved by 48% of patients taking Risperdal. The medication was also shown to improve depressive symptoms and was better tolerated than haloperidol.
A study published in the Journal of Clinical Psychiatry found that divalproex improved mood and behavioral disorders in over 78% of at-risk children. The medication may delay or prevent the onset of bipolar disorder, offering an alternative treatment option.
A study of 817 patients who underwent bypass surgery found that treating depression could significantly reduce mortality rates. Patients with moderate to severe depression at baseline and those with mild depression sustained from initial to six-month assessment were more than twice as likely to die than patients who were not depressed.
Researchers at Duke University Medical Center found that depression is a strong independent risk factor for death in patients undergoing coronary artery bypass surgery. Depression was associated with a doubling of the risk of death during the follow-up period, regardless of other factors.
A study led by Constantine Lyketsos found that sertraline hydrochloride significantly improved the quality of life and reduced functional decline in Alzheimer's patients with depression. The treatment showed a positive influence on 84% of participants, while only 35% in the placebo group experienced improvements.
Researchers found that a specific gene variant interacts with stressful events to predict depression risk, with individuals carrying a short allele more vulnerable to depression after stress. The study's findings suggest new potential treatments and diagnostic techniques for millions of people worldwide affected by depression.
A study published in Molecular Psychiatry has identified a sex-specific gene variant associated with an increased risk of developing severe depression in women. Over 80% of women who inherited the CREB1 variant developed depressive disorders, highlighting the importance of considering sex-specific factors in depression research.
Two studies clarify that ADHD and BPD are distinct disorders that can occur in adults, and identify bupropion as a possible treatment for both conditions. The medications used to treat ADHD may exacerbate manic symptoms, but addressing both disorders is crucial for improved functioning and well-being.
Researchers at the University of Pittsburgh Medical Center have identified 19 genetic loci associated with depressive disorders, which may lead to more effective treatments. The study also found that individuals with these genes had a significantly reduced lifespan, particularly in children.
A UCLA-led study found that individuals with bipolar depression who continued taking antidepressants in conjunction with mood stabilizer medication after remission had a lower risk of depression relapse. The study's lead author, Dr. Lori Altshuler, suggests guidelines similar to those for unipolar depression may be more effective.
A recent study by Harvard Medical School found that millions of Americans suffer from major depressive episodes (MDE), with the majority being severe cases. The researchers measured the severity and duration of depression in over 9,000 Americans and found that only one in five received adequate treatment for their condition.
A new study published in the Journal of the American Medical Association found that treating depression and social isolation in heart attack patients does not improve survival rates, but significantly improves quality of life. The ENRICHD trial followed 2,481 heart attack patients with depression or low social support for 29 months.
Quetiapine has been shown to be statistically more effective at treating manic symptoms of bipolar disorder than placebo. The results of the clinical trials indicate rapid symptom improvement from day four and a favorable side effect profile, making it an exciting development in psychiatry.
A recent study found that 20% of pregnant women show signs of depression, yet only 13.8% receive mental health counseling or treatment during pregnancy. The study highlights the need for increased awareness and screening to address post-partum depression risks associated with hormone imbalances and fetal exposure.